drs. M. Nijland

No picture available
m.nijland umcg.nl


  1. Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

    van der Meulen, M., Bakunina, K., Nijland, M., Minnema, M. C., Cull, G., Stevens, W. B. C., Baars, J. W., Mason, K. D., Beeker, A., Beijert, M., Taphoorn, M. J. B., van den Bent, M. J., Issa, S., Doorduijn, J. K., Bromberg, J. E. C. & Dirven, L., 1-Aug-2020, In : Annals of Oncology. 31, 8, p. 1046-1055 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Late relapses in diffuse large B-cell lymphoma: where to move next?

    Nijland, M. & Kluin-Nelemans, H. C., 15-Apr-2020, In : Leukemia & Lymphoma. 61, 5, p. 1005-1006 2 p.

    Research output: Contribution to journalEditorialAcademicpeer-review

  3. Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma

    Nijland, M., Bakker, M., Meijer, K. & Plattel, W., 15-Apr-2020, In : Annals of Hematology. 12, p. 2947-2948 2 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

  4. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

    Kersten, M. J., Driessen, J., Zijlstra, J. M., Plattel, W. J., Morschhauser, F., Lugtenburg, P. J., Brice, P., Hutchings, M., Gastinne, T., Liu, R., Burggraaff, C. N., Nijland, M., Tonino, S. H., Arens, A. I. J., Valkema, R., van Tinteren, H., Lopez-Yurda, M., Diepstra, A., De Jong, D. & Hagenbeek, A., 9-Apr-2020, In : Haematologica.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (44) »

Press / Media
  1. Medtalks:Diffuus Grootcellig B-cellymfoom 2018

    Marcel Nijland


    1 Media contribution

    Press/Media: Expert CommentProfessional

View all (1) »

ID: 59823087